Biogen

#News: Today, we received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (#CHMP) for our postpartum depression (#PPD) treatment. Read the news here: bit.ly/4lIeqCt

#News: We’re committed to driving innovation to help redefine what’s possible for the care of spinal muscular atrophy (SMA). We’re excited to share results from our ongoing research at the @CureSMA annual conference. Learn more about our findings: ow.ly/2lTw50WhuHC

#News: We're thrilled to attend the Alzheimer's Association International Conference (#AAIC) 2025 to share updates from our Alzheimer's disease portfolio. Read more here: bit.ly/3IDprqe

#News: Today, we announced plans to invest $2 billion in our existing manufacturing footprint in North Carolina’s Research Triangle Park site to support our late-stage pipeline. Learn more about this news here: bit.ly/44E6c8y

#News: With @StokeTx, we announced new data from studies for an investigational medicine for Dravet Syndrome. Data were presented at the 16th European Paediatric Neurology Society Congress. Read the news here: bit.ly/3GkGwVc

Biogen will report Q2 2025 financial results on July 31st before markets open in the U.S. Learn more: ow.ly/N2ZX50WiGUB #Earnings $BIIB

#News: Exciting progress is underway as we begin the Phase 3 study of our investigational therapy for kidney disease in adults with primary membranous nephropathy (PMN). Learn more: bit.ly/4nJwA8D

#News: Our latest data from a phase 1 study evaluates our novel investigational SMA therapy and supports our efforts to address the needs of SMA patients. Read more about our research presented at the @CureSMA conference: ow.ly/y1KU50WfZnP

#News: We announced the initiation of the Phase 3 Pediatric Study of an investigational form of medicine for Friedreich ataxia (FA). Learn about this news: bit.ly/4laU9F5

Our CEO and leadership team shared key insights about our rare kidney disease program. As we continue to advance research, our goal is to bring additional care options to patient populations living with kidney disease. Listen now: ow.ly/EgQc50Wb01O

#News: Along with @ucb_news, we are pleased to share data from our phase 3 clinical trial evaluating our investigational lupus therapy at #EULAR2025. Read more: ow.ly/tUrm50W8jNu

#News: Today we’re hosting a virtual investor seminar to highlight the potential of our investigational therapy for a range of immune-mediated diseases, including three Phase 3 programs in rare kidney diseases. Learn more and join us at 10 a.m. ET: bit.ly/45XhbL4

Building on the success of our existing programs, we’re continuing to advance R&D efforts to help make an impact for patients. Learn about the developments in our rare disease pipeline with insights from Biogen's CEO and leadership team. Register today: ow.ly/3zkR50W3pjx

Our Head of Development attended @FTPharma to discuss the role of AI strategy in advancing our late-stage pipeline. Joining industry leaders in these discussions is vital as we continue to explore the impact of AI in biopharma.

#News: With @CityTx_ we announced a new research collaboration to develop select novel RNAi-based therapies. Learn more about this announcement: bit.ly/3FtlSBA

Collaboration with other industry experts at events like @LupusCongress provides us with valuable insights to help drive progress for people living with lupus. We look forward to attending #LUPUS2025. Learn about our work: ow.ly/srhu50VWE9i

We’re transforming what’s possible in neurology, immunology, and rare diseases by following promising science and establishing strategic partnerships. See how we’re making important progress in our pipeline to help advance health outcomes.

Our Q1 financial results support our strategy for long-term growth. We aim to bring innovative medicines to patients while generating value for our shareholders. Read more: ow.ly/1MG650VLAgP